Adherence to cardiomyopathy screening guidelines among adolescent and young adult cancer survivors exposed to chest radiation and/or anthracyclines.

Szczegóły
Abstrakt

Tytuł:: Adherence to cardiomyopathy screening guidelines among adolescent and young adult cancer survivors exposed to chest radiation and/or anthracyclines.
Autorzy:: Tanenbaum HC; Parabel USA, 1991 74th Avenue, Suite B, Vero Beach, FL, 32966, USA.
Wolfson J; School of Medicine, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, 35233, USA.
Xu L; MedHealth Statistical Consulting Inc., 6848 Silkwood Ln, Solon, OH, 44139, USA.
Hahn EE; Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles Ave, Pasadena, CA, 91101, USA.
Bhatia S; School of Medicine, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL, 35233, USA.
Cannavale K; Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles Ave, Pasadena, CA, 91101, USA.
Cooper R; Department of Pediatrics-Hematology/Oncology, Kaiser Permanente Southern California, 1526 N Edgemont St, Los Angeles, CA, 90027, USA.
Chao C; Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles Ave, Pasadena, CA, 91101, USA. .
Źródło:: Journal of cancer survivorship : research and practice [J Cancer Surviv] 2021 Oct; Vol. 15 (5), pp. 738-747. Date of Electronic Publication: 2020 Nov 10.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
Język:: English
Imprint Name(s):: Original Publication: New York, N.Y. : Springer Science + Business Media, c2007-
MeSH Terms:: Cancer Survivors*
Cardiomyopathies*
Neoplasms*
Adolescent ; Adult ; Anthracyclines/adverse effects ; Early Detection of Cancer ; Humans ; Survivors ; Young Adult
References:: JAMA Netw Open. 2018 Jun 1;1(2):e180350. (PMID: 30646082)
J Clin Oncol. 2008 Mar 1;26(7):1073-9. (PMID: 18309941)
JNCI Cancer Spectr. 2019 Aug 01;3(4):pkz057. (PMID: 32337483)
Pediatr Blood Cancer. 2016 Feb;63(2):337-43. (PMID: 26488337)
Circulation. 2013 Oct 22;128(17):1927-95. (PMID: 24081971)
Cancer. 2016 Apr 1;122(7):1009-16. (PMID: 26848927)
Cancer. 2016 Apr 1;122(7):988-99. (PMID: 26849003)
Pediatr Blood Cancer. 2011 Sep;57(3):467-72. (PMID: 21280201)
J Cancer Surviv. 2019 Aug;13(4):547-557. (PMID: 31250352)
J Cancer Surviv. 2012 Jun;6(2):155-62. (PMID: 22170442)
Lancet Oncol. 2015 Mar;16(3):e123-36. (PMID: 25752563)
J Cancer Surviv. 2017 Oct;11(5):614-623. (PMID: 28785871)
J Pediatr Hematol Oncol. 2014 Mar;36(2):118-24. (PMID: 24309612)
J Clin Oncol. 2016 May 10;34(14):1626-33. (PMID: 26951318)
Cancer. 2012 Oct 1;118(19):4884-91. (PMID: 22688896)
J Clin Oncol. 2004 Dec 15;22(24):4979-90. (PMID: 15576413)
J Clin Oncol. 2014 May 20;32(15):1578-85. (PMID: 24752057)
J Natl Compr Canc Netw. 2012 Sep;10(9):1112-50. (PMID: 22956810)
Oncologist. 2015 Feb;20(2):186-95. (PMID: 25568146)
Cancer. 2011 May 15;117(10 Suppl):2335-41. (PMID: 21523755)
Cancer. 2019 May 1;125(9):1558-1567. (PMID: 30620388)
J Natl Cancer Inst Monogr. 2010;2010(40):25-30. (PMID: 20386051)
J Clin Oncol. 2012 Dec 10;30(35):4401-8. (PMID: 23091100)
Cancer. 2011 May 15;117(10 Suppl):2295-300. (PMID: 21523749)
Health Serv Res. 2004 Jun;39(3):511-30. (PMID: 15149476)
Am J Prev Med. 2007 Oct;33(4):291-6. (PMID: 17888855)
JAMA. 2017 Feb 28;317(8):814-824. (PMID: 28245323)
Grant Information:: R21 CA198042 United States CA NCI NIH HHS; 1R21CA198042-01A1 United States CA NCI NIH HHS
Contributed Indexing:: Keywords: AYA; Adolescents and young adults; Cardiomyopathy; Late effects; Survivorship
Substance Nomenclature:: 0 (Anthracyclines)
Entry Date(s):: Date Created: 20201110 Date Completed: 20211125 Latest Revision: 20221003
Update Code:: 20240105
PubMed Central ID:: PMC8107185
DOI:: 10.1007/s11764-020-00965-w
PMID:: 33170480
: Czasopismo naukowe

Full Text Finder

Purpose: Cancer survivors are at risk for late effects from therapeutic exposures, including cardiovascular complications. To improve outcomes among adolescents and young adults (AYA) with cancer, the National Comprehensive Cancer Network (NCCN) released guidelines for screening services (based on the Children's Oncology Group Long-Term Follow-Up [LTFU] guidelines) for survivors of AYA cancer. To better understand survivorship care gaps, we conducted a baseline evaluation of cardiomyopathy screening among survivors of AYA cancers.
Methods: Members of Kaiser Permanente Southern California diagnosed with cancer between ages 15 and 39 from 2000 to 2010 with at least 5-year survival after diagnosis who were exposed to chest radiation and/or anthracyclines were included. We calculated the Prevention Index ([PI], proportion of person-time covered by receipt of preventive services relative to the total person-time eligible) to evaluate adherence to recommended cardiomyopathy screenings based on the LTFU through 2016. Predictors for screening were evaluated in multivariable logistic regression.
Results: Among 479 survivors recommended for cardiomyopathy screening, 28 received at least one screening, and the mean PI was 2.38% (SD = 13.05%, median = 0.00%). Compared to stage I, survivors of stage II (odds ratio [OR] = 5.56 [1.05-29.46]) and stage III/IV cancer (OR = 6.08 [1.10-33.54]) were more likely to receive cardiomyopathy screening.
Conclusions: Cardiomyopathy screening among survivors was low around the time when NCCN AYA oncology guidelines were released.
Implications for Cancer Survivors: Our study highlights significant room for improvement for adherence to cardiomyopathy screening recommendations among survivors of AYA cancer. Attention is needed to ensure that recommended cardiomyopathy screenings are met for better management of cardiomyopathy late effects.
(© 2020. Springer Science+Business Media, LLC, part of Springer Nature.)

Informacja